Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ASP II (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute Ischemic Stroke

NCT00300196 is registered in ClinicalTrials.gov with Neurobiological Technologies as lead sponsor.

NCT NCT00300196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00300196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ASP II (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute Ischemic Stroke
Lead sponsor
Neurobiological Technologies
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2006
Completion date
December 31, 2008
Enrollment
311 (actual)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

brain infarction, cerebral ischemia, stroke